What was the market valuation of the South Korea gene editing market in 2024?

The market valuation was $173.8 Million in 2024. Read More

What is the projected market valuation for the South Korea gene editing market by 2035?

The projected valuation for 2035 is $1407.34 Million. Read More

What is the expected CAGR for the South Korea gene editing market during the forecast period 2025 - 2035?

The expected CAGR is 20.94% during the forecast period 2025 - 2035. Read More

Which technology segment had the highest valuation in 2024?

The CRISPR technology segment had the highest valuation at $69.14 Million in 2024. Read More

What are the key applications driving the South Korea gene editing market?

Key applications include genetic engineering, valued at $69.52 Million, and clinical applications, valued at $104.28 Million in 2024. Read More

What methods are utilized in the South Korea gene editing market?

The Ex-vivo method was valued at $69.14 Million, while the In-Vivo method reached $104.66 Million in 2024. Read More

Who are the major end users in the South Korea gene editing market?

Major end users include biotechnology and pharmaceutical companies, valued at $69.52 Million, and contract research organizations (CROs), valued at $52.14 Million in 2024. Read More

Which companies are considered key players in the South Korea gene editing market?

Key players include CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, and Regeneron Pharmaceuticals. Read More

What was the valuation of the TALEN technology segment in 2024?

The TALEN technology segment was valued at $34.57 Million in 2024. Read More

How does the market for gene editing in South Korea compare to other regions?

While specific comparisons are not provided, the South Korea gene editing market is expected to grow significantly, indicating a robust development trajectory. Read More

South Korea Gene Editing Market

South Korea Gene Editing Market Research Report: Size, Share, Trend Analysis By Technology (CRISPR, TALEN, ZFN, Antisense, others), By Applications (Genetic Engineering, Gene Therapy, Cell Line Engineering, Others), By Method (Ex-vivo, In-vivo) and By End Users (Biotechnology and Pharmaceutical Companies, Contract Research Organizations (CROs), Academic and amp; Government Research Institutes) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

20.94%

2024 Market Size

$ 173.8 Million

2035 Market Size

$ 1,407.34 Million

Life Sciences ● Updated February 2026 Report ID: MRFR/LS/51137-HCR | Pages: 200 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Technology (USD Million)
  1. 4.1.1 CRISPR
  2. 4.1.2 TALEN
  3. 4.1.3 ZFN
  4. 4.1.4 antisense
  5. 4.1.5 others
2. 4.2 Life Sciences, BY Application (USD Million)
  1. 4.2.1 genetic engineering
  2. 4.2.2 clinical application
3. 4.3 Life Sciences, BY Method (USD Million)
  1. 4.3.1 Ex-vivo
  2. 4.3.2 In-Vivo
4. 4.4 Life Sciences, BY End User (USD Million)
  1. 4.4.1 biotechnology and pharmaceutical companies
  2. 4.4.2 contract research organizations (CROs)
  3. 4.4.3 academic & government research institutes
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 CRISPR Therapeutics (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Editas Medicine (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Intellia Therapeutics (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Regeneron Pharmaceuticals (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sangamo Therapeutics (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Vertex Pharmaceuticals (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Amgen (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Bayer (DE)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Novartis (CH)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY
3. 6.3 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
4. 6.4 SOUTH KOREA MARKET ANALYSIS BY METHOD
5. 6.5 SOUTH KOREA MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY TECHNOLOGY, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
14. 6.14 LIFE SCIENCES, BY APPLICATION, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY APPLICATION, 2024 TO 2035 (USD Million)
16. 6.16 LIFE SCIENCES, BY METHOD, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY METHOD, 2024 TO 2035 (USD Million)
18. 6.18 LIFE SCIENCES, BY END USER, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TECHNOLOGY, 2025-2035 (USD Million)
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY METHOD, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

South Korea South Korea Gene Editing Market Segmentation

South Korea Gene Editing Market By South Korea Gene Editing Market (USD Million, 2025-2035)

CRISPR
TALEN
ZFN
antisense
others

South Korea Gene Editing Market By Application (USD Million, 2025-2035)

genetic engineering
clinical application

South Korea Gene Editing Market By Method (USD Million, 2025-2035)

Ex-vivo
In-Vivo

South Korea Gene Editing Market By End User (USD Million, 2025-2035)

biotechnology and pharmaceutical companies
contract research organizations (CROs)
academic & government research institutes

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”